Lifecore Biomedical to Participate at CDMO Live Europe

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe.

GlobeNewsWire • 2 hours ago

Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 6, 2026

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, before the market opens.

GlobeNewsWire • Apr 29, 2026

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on April 20, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 5,000 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

GlobeNewsWire • Apr 22, 2026

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit.

GlobeNewsWire • Apr 8, 2026

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCR

SAINT PAUL, Minn., April 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP and The Rosen Law Firm, P.A. announce that the United States District Court District of Minnesota has approved the following announcement of a proposed class action settlement that would benefit purchasers of Lifecore Biomedical, Inc. Securities (NASDAQ: LFCR):

GlobeNewsWire • Apr 6, 2026

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.

GlobeNewsWire • Mar 26, 2026

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product.

GlobeNewsWire • Mar 23, 2026

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 16, 2026